Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients

Summary

SPH3127 tablet is a of renin inhibitor. It is expected to be a new drug for essential hypertension. This is a phase IIa trial which designed to evaluate its efficacy and safety on treating mild-moderate essential hypertension patients.

Timeline

Start

2019-01-11

Primary completion

2020-06-30

Completion

2020-06-30

Publications

• Wang F, Liu L, Ruan H, Chen X, Zhang Y, Yu Z, Li Y, Guan Y, Wang J, Huang K, Yu S, Cao Y, Ding C, Chang L, Huang Y, Chen X, Lv Q, Ma C. A randomized, double-blind, placebo-controlled, phase IIa, clinical study on investigating the efficacy and safety of SPH3127 tablet in patients with essential hypertension. Hypertens Res. 2024 Jul;47(7):1925-1933. doi: 10.1038/s41440-024-01657-z. Epub 2024 Apr 17.

Drugs

Indications